2007 Scientific Meeting

2007 Annual Scientific Meeting


Thursday, November 29
9:00 – 9:30 AM Welcome, Chairman Remarks and Introductions
Steve Case
Chairman, Accelerate Brain Cancer Cure
Dr. David Agus, External Scientific Advisor to Accelerate Brain Cancer Cure
9:30 – 10:30 AM Panel 1: Evolution of Avastin
Initial data from a phase 2 clinical trial at Duke pointed to the clinical activity of Avastin based therapy in patients with GBM. Subsequent clinical data from other institutions led to a randomized clinical trial of Avastin versus Avastin/CPT-11. The clinical experience of patients treated on this trial was extremely positive. This session will examine the evolution of this therapy and clinical/ biology lessons learned, the therapy from a patient’s perspective, and discuss some of the findings from the clinical trials from Genentech’s perspective. We hope to gain a sense of where we are with Avastin-based therapy and where we are going as a field.
Moderated by Dr. David Agus
Dr. Henry Friedman, Co-Director, Neuro-Oncology Program at Duke University Medical Center
Dr. Robert Mass, Principal Medical Director, BioOncology, Genentech, Inc.
Woodrow Jarrell, Patient of Dr. Henry Friedman at Duke University Medical Center
- 10 min. break -
10:40 – 12:00 PM Panel 2: Technology Advances
Clear advances in technology have allowed classification of GBM by pathway identification, gene expression, genetic changes, etc. This session will discuss the technology advances and the potential to apply these to patients with GBM now. The emphasis will be on the translation of the exciting advances both in clinical trials and in clinical practice.
Moderated by Greg Simon, Faster Cures
Dr. Anna Barker, Deputy Director, National Cancer Institute
Dr. Ken Buetow, Program Director, Center for Bioinformatics, National Cancer Institute
Dr. David Parkinson, President and CEO, Nodality, Inc.
Dr. Beth Seidenberg, Kleiner Perkins Caufield & Byers
1:30 - 2:30 PM Panel 3: Cancer Stem Cells
The existence of cancer stem cells has been demonstrated by several groups in GBM tumors. Therapy, to date, has targeted the ‘other’ GBM cells in the tumor which are the clear majority. The role of these cells in providing resistance to current therapies is evolving. This session will address the role of cancer stem cells and potential treatments to target these cells.
Moderated by Dr. Darrell Bigner, Duke
Dr. Irving Weissman, Director, Comprehensive Cancer Center,
Stanford University - Invited
Dr. John Lewicki, Senior VP Research and Development, OncoMedr
- 15 min. break -
2:45 – 3:45 PM Panel 4: Vaccines
We have heard over the past years of various vaccine strategies for the treatment of GBM. Recent pilot data with some of these approaches has been encouraging and this data as well as the ongoing clinical trials will be presented. In addition, advances of new strategies from other cancers will be presented with the goal of expediting these findings to benefit patients with GBM.
Moderated by Dr. David Agus
Dr. John Sampson, Asst. Professor, Division of Neuro-surgery, Duke University Medical Center
Dr. Andrew Parsa, Principal Investigator, Brain Tumor Research Center, UCSF
Friday, November 30
9:00 – 10:00 AM Closing Session
Looking Ahead — Funding Priorities 2008 and Beyond
The closing session is an opportunity for reflection on Thursday’s discussions with a focus on the future of brain cancer research and funding priorities. We’ll ask public and private funders, as well as corporations, to discuss their research agendas in 2008 and beyond. We’ll also touch on how to leverage resources to fund even more complex initiatives through collaboration.